Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2CTx-1301 is the First, True, Once-Daily Stimulant Medication to ...

The parts of the brain needed to remember words have been identified. Those areas are affected by a common form of epilepsy, ...

The parts of the brain that are needed to remember words, and how these are affected by a common form of epilepsy, have been ...

Abbott's Jenn Wong discusses the TRANSCEND trial for depression, imaging tech advancing DBS, and other potential applications ...

CING READ THE FULL CING RESEARCH REPORT Since the report of third quarter results, Cingulate, Inc. (NASDAQ:CING) has executed ...

Cingulate Inc. submitted CTx-1301 Phase 3 safety data to the FDA, preparing for a Pre-NDA meeting on April 2, 2025. Cingulate Inc. announced the submission of Phase 3 safety data for its ADHD ...

A new study has identified brain regions crucial for remembering words and how they are affected in people with temporal lobe epilepsy.

The subtleties involved here reflect the fact that the brain’s dizzying complexity means it’s rarely possible to draw simple conclusions. Even in this case, where a basic interpretation might be that ...

Explore Cingulate stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CING. EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

KANSAS CITY, Kan., March 04, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery ...